ReviewClinical and translational allergy2026
Integrated Immune, Epithelial and Lipid Pathways in NSAID-Exacerbated Respiratory Disease.
Review in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NSAID-exacerbated respiratory disease (N-ERD) is a chronic inflammatory disorder characterized by asthma, chronic rhinosinusitis with nasal polyps and respiratory reactions to cyclooxygenase-1 inhibiting nonsteroidal anti-inflammatory drugs (NSAID). Its pathogenesis involves dysregulated arachidonic acid metabolism, epithelial barrier dysfunction and activation of multiple immune cell types, including eosinophils, mast cells, macrophages, basophils, and innate lymphoid cells. Recent genomic and transcriptomic analyses have revealed variants in genes linked to epithelial integrity and cellular interactions, metabolic and epigenetic reprogramming of monocyte-derived macrophages that promotes persistent proinflammatory activity. Emerging biomarkers, such as 15-oxo-eicosatetraenoic acid (15-oxo-ETE), acylcarnitines, apolipoprotein E, oncostatin M, surfactant protein D, retinoic acid and glial cell line-derived neurotrophic factor provide novel mechanistic insights. A recently proposed Aspirin Hypersensitivity Diagnostic Index, integrating urinary leukotriene E4 (LTE4) and 15-oxo-ETE with sinus computed tomography (CT) scoring, may offer a practical noninvasive diagnostic tool. Inflammatory endotyping highlights substantial heterogeneity in N-ERD, encompassing T2-dominant, T1-, T3-related and neutrophilic inflammatory patterns, which may coexist or vary across airway compartments and influence clinical presentation and treatment response. As therapeutic strategies evolve, biologic agents targeting T2 pathways are becoming increasingly central, while aspirin therapy after desensitization may be reserved for selected patients. This review aims to summarize current mechanistic insights into the immune, epithelial, and lipid pathways involved in N-ERD, with a particular focus on emerging biomarkers and inflammatory endotypes relevant to diagnosis and personalized therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.